Interpretation of the World Health Organization's Use of targeted next-generation sequencing to detect drug-resistant tuberculosis Rapid communication, 2023

doi:10.19982/j.issn.1000-6621.20230311

Abstract

Abstract:

The World Health Organization released “Use of targeted next-generation sequencing to detect drug-resistant tuberculosis Rapid communication,2023” recently, in order to timely share the important data and opinions formed accordingly on drug resistance detection by the targeted next-generation sequencing technique. Therefore, facilitate the understanding of this new technique and accelerate its promotion. This note interpreted the key data and the opinions in the rapid communication, so as to help the reader to recognize the value of the targeted next-generation sequencing technique in the diagnosis of drug resistant tuberculosis.

Key words: Mycobacterium tuberculosis, Drug resistance, bacterial, Diagnostic techniques and procedures, Genes, bacterial, Consensus development conferences as topic

CLC Number:

R52
R825.2

Huang Hairong. Interpretation of the World Health Organization's Use of targeted next-generation sequencing to detect drug-resistant tuberculosis Rapid communication, 2023[J]. Chinese Journal of Antituberculosis, 2023, 45(10): 921-924. doi: 10.19982/j.issn.1000-6621.20230311

References 12

[1]	高通量测序共识专家组. 高通量测序技术在分枝杆菌病诊断中的应用专家共识. 中华传染病杂志, 2023, 41(3):175-182. doi:10.3760/cma.j.cn311365-20221203-00492.
[2]	World Health Organization. Use of targeted next-generation sequencing to detect drug-resistant tuberculosis Rapid communication, 2023. Geneva: Word Health Organization, 2023.
[3]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis-rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organi-zation, 2021.
[4]	Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med, 2017, 377(11): 1043-1054. doi:10.1056/NEJMoa1614915.
[5]	Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol, 2008, 26(10): 1135-1145. doi:10.1038/nbt1486. pmid: 18846087
[6]	Goig GA, Torres-Puente M, Mariner-Llicer C, et al. Towards next-generation diagnostics for tuberculosis: identification of novel molecular targets by large-scale comparative genomics. Bioinformatics, 2020, 36(4):985-989. doi:10.1093/bioinformatics/btz729. pmid: 31580405
[7]	Van Deun A, Wright A, Zignol M, et al. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis, 2011, 15(1): 116-124. pmid: 21276307
[8]	World Health Organization. Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex. Geneva: Word Health Organization, 2022.
[9]	Xu J, Wang B, Hu M, et al. Primary Clofazimine and Beda-quiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother, 2017, 61(6): e00239-17. doi:10.1128/AAC.00239-17.
[10]	Kaniga K, Aono A, Borroni E, et al. Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study. J Clin Microbiol, 2020, 58(4): e01677-19. doi:10.1128/JCM.01677-19.
[11]	Kaniga K, Hasan R, Jou R, et al. Bedaquiline Drug Resis-tance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. J Clin Microbiol, 2022, 60(1): e0291920. doi:10.1128/JCM.02919-20.
[12]	World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. Geneva: Word Health Organization, 2018.

[1]	Chen Ruiqi, Zhang Mingwu, Wang Wei, Chen Songhua, Liu Zhengwei, Chen Bin. Prevalence and influencing factors of latent tuberculosis infection among elderly rural residents in Changshan County, Zhejiang Province [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 383-389.
[2]	Li Xueqiu, Kuang Haobin, Wang Ting, Min Fei, Tao Lan, Cao Xihui, Li Xiang, Liu Guobiao. Analysis of self-paid medical expenses and influencing factors for multidrug-resistant tuberculosis patients in Guangzhou City [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 411-417.
[3]	Shang Xuetian, Dong Jing, Huang Mailing, Sun Qi, Jia Hongyan, Zhang Lanyue, Liu Qiuyue, Yao Mingxu, Wang Yingchao, Ji Xiuxiu, Du Boping, Xing Aiying, Pan Liping. Transcriptome study on peripheral blood mononuclear cells of latent tuberculosis infection individuals [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 449-460.
[4]	Pei Shaojun, Ou Xichao. Interpretation of the World Health Organization’s Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance (2nd Edition) [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 260-266.
[5]	National Center of Medical Quality Control for Respiratory Diseases , Tuberculosis Branch of Chinese Medical Association , Tuberculosis Control Branch of Chinese Antituberculosis Association , China-Japan Friendship Hospital . Clinical practice guidelines for early detection of pulmonary tuberculosis in general medical facilities [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 127-140.
[6]	Zhang Jing, Fu Ruonan, Wang Senlu, Feng Jianyu, Zhang Ling, Gulina Badeerhan, Zulikatiayi Abudula, Wang Xinqi. Analysis of willingness of receiving preventive treatment in patients with latent tuberculosis infection among close contacts of pulmonary tuberculosis in high-burden areas [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 165-172.
[7]	Shang Xuetian, Pan Liping. Role of tissue kallikrein family in pathogenesis of microorganism infection [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 239-244.
[8]	He Yijun, Cheng Jun, Gao Lei. Epidemiological investigation of latent tuberculosis infection should be carried out systematically [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 1-7.
[9]	Zhang Lifan, Ma Yanan, Zou Xiaoqing, Zhang Yueqiu, Zhang Fengchun, Zeng Xiaofeng, Zhao Yan, Liu Shengyun, Zuo Xiaoxia, Wu Huaxiang, Wu Lijun, Li Hongbin, Zhang Zhiyi, Chen Sheng, Zhu Ping, Zhang Miaojia, Qi Wencheng, Liu Yi, Liu Huaxiang, Shi Xiaochun, Liu Xiaoqing, the Epidemiological Study and Therapeutic Evaluation of Rheumatic Patients with Tuberculosis Study Team. Latent tuberculosis infection rate and risk factors in patients with rheumatic diseases: a multi-center, cross-sectional study [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 29-39.
[10]	Zhang Guoqin, Wei Wenliang, Zhang Zhi, Zhang Yuhua, Zhong Da, Zhang Fan. Factors for discrepancy between two methods in testing latent tuberculosis infection and effect of preventive anti-tuberculosis treatment among prisoners [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 45-53.
[11]	Liu Mei, Wu Xia, Gu Xu, Li Nana, Zhang Wanmin, Zhang Xiaoke, Lan Yuanbo. Evaluation of the performance of InnowaveDX MTB/RIF in detecting Mycobacterium tuberculosis complex and rifampicin resistance [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 70-74.
[12]	Qin Huifang, Liang Xiaoyan, Zhou Lingyun, Lan Yumei, Lin Mei, Zhang Zhitong, Huang Yan, Wei Xiaolin, Liang Dabin. Analysis on the effect of GeneXpert MTB/RIF single test and mixed test on sputum samples for actively screening tuberculosis in key population of Guangxi [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 880-884.
[13]	Bi Xiuli, Geng Hong, Jin Jin. The role of myeloid system and CD4⁺T cells in Mycobacterium tuberculosis infection and immunopathology [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 904-912.
[14]	Guo Tonglei, Xin Henan, Gao Lei. Interpretation of WHO consolidated guidelines on tuberculosis: Module 1: prevention: tuberculosis preventive treatment [J]. Chinese Journal of Antituberculosis, 2023, 45(8): 723-727.
[15]	Huang Wenbin, Chen Liping, Zhang Wang, Xiao Ting, Zhang Mane, Wu Dingchang. Establishment of a cross primer isothermal amplification technique for rapid detection of Mycobacterium tuberculosis complex and nontuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2023, 45(8): 734-743.